Full text
Earnings transcript
Read the complete earnings call transcript.
GLPG
Galapagos N.V.
$29.42
-0.34
(-1.14%)
| Exchange: | NASDAQ |
| Market Cap: | 1.939B |
| Shares Outstanding: | 5.939M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Henry Gosebruch | |||||
| Full Time Employees: | 704 | |||||
| Address: |
| |||||
| Website: | https://www.glpg.com |
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 239,724 | 275,649 | 1,112,200 |
| Gross Profit | 239,724 | 240,786 | 623,100 |
| EBITDA | 51,037 | 43,325 | 556,976 |
| Operating Income | -88,263 | -188,338 | 501,391 |
| Net Income | 211,697 | 74,082 | 320,900 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 4,357,396 | 4,135,719 | 3,405,068.168 |
| Total Liabilities | 1,561,830 | 1,238,780 | 170,577.370 |
| Total Stockholders Equity | 2,795,566 | 2,896,939 | 3,234,490.797 |
| Total Debt | 9,596 | 11,722 | 12,095.848 |
| Cash and Cash Equivalents | 166,803 | 64,239 | 87,830.602 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -405,970 | -320,026 | 0 |
| Capital Expenditure | -19,273 | -82,110 | 0 |
| Free Cash Flow | -425,243 | -402,136 | 0 |
| Net Income | 211,697 | 74,082 | 320,900 |
| Net Change in Cash | -341,307 | -102,571 | -64,239 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 18,654.159 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 73,689.203 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 48,298.372 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 2,532.286 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 10,003.248 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 6,556.464 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | -257,707.740 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | -30,938.186 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | -153,085.773 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 6,038.031 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 23,851.931 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 15,633.354 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | -2.320 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | -0.470 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | -3.910 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 2 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust R&D Pipeline and Innovation Focus: Galapagos demonstrates a strong commitment to research and development, as highlighted in the Q1 2025 earnings call transcript. The company is advancing multiple clinical programs, particularly in immunology and oncology, positioning it as a leader in innovative therapeutic solutions within the biotechnology sector.
- Strategic Business Restructuring: The decision to separate SpinCo, as noted in the Q1 2025 update, aims to enhance value creation and focus on core therapeutic areas. This strategic move could streamline operations and improve investor confidence in the company’s long-term growth potential.
- Solid Financial Position: Based on balance sheet data, Galapagos maintains significant cash and cash equivalents alongside total current assets, providing liquidity to fund ongoing R&D and operational needs without immediate financial strain.
- Positive Industry Positioning: Performance metrics indicate that Galapagos operates in a competitive biotechnology industry within the healthcare sector. Its performance trends (e.g., perf1y, perf5y) suggest alignment with or outperformance of industry averages, reflecting resilience and market relevance.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about GLPG valuation
Is Galapagos N.V. (GLPG) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Galapagos N.V. (GLPG) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is GLPG a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether GLPG trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is GLPG’s P/E ratio?
You can see GLPG’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for GLPG?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is GLPG a good long-term investment?
Whether GLPG fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
GLPG
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-1.14
Trading Metrics:
| Open: | 29.29 | Previous Close: | 29.76 | |
| Day Low: | 29.06 | Day High: | 29.6 | |
| Year Low: | 22.59 | Year High: | 37.78 | |
| Price Avg 50: | 32.93 | Price Avg 200: | 32.21 | |
| Volume: | 175547 | Average Volume: | 142796 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeGLPG full analysis
Welcome to MARKETSNAP’s SWOT analysis for Galapagos, a biotech player that’s been making waves in the industry. If you’re not familiar with Galapagos, let me give you the quick rundown. This is a Belgium-based company operating in the biotechnology sector, focusing on developing innovative therapies for inflammatory and fibrotic diseases, among other areas. They’ve carved out a niche in a highly competitive space, and with a decent market cap, they’re not a small fish in the pond. Today, we’re diving…
